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Abstract: This paper proposes the Effective Index, a formal tool to support decision
processes in drug discovery. The Effective Index is based on concurrency theory and
process calculi to describe incrementally complex biological systems and on Markov
process theory to handle quantitative information. A running case study concerning the
pathways and the drugs related to hypertension exploits the approach.
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1. INTRODUCTION
Pharmacodynamics (Macheras and Iliadis, 2005) is
the study of biochemical and physiological effects of
drugs, mechanisms of drug action and relationship
between drug concentration and effect. The effect of
a drug on the body is influenced by many factors, as
age, genetic makeup and disorders other than the one
being treated. Methods and techniques that account
the complexity of the biological data and enable pre-
diction on the whole system are required. Therefore
pharmacodynamics is moving towards a systems bi-
ology approach (Kitano, 2001). Systems biology ex-
ploits the relationships between all the components
rather than approaching them in isolation (Butcher et
al., 2004). The community agrees that predicting the
absorption, distribution, metabolism, excretion and
toxicity (ADME/Tox) properties of drug compounds
may prevent failure of some molecules to reach the
clinic trial stage (see e.g., (Ekins et al., 2005; Bugrim
et al., 2004)). The focus is on preclinical ADME/Tox
studies, where a system approach might improve the
understanding of drug effects.
Various approaches based on differential equations
(Jones and Sleeman, 2003) have been applied to de-
scribe and study the kinetic of cellular processes.
Some authors (Hlavacek et al., 2006) claim that it
could be hard to investigate the behaviour of systems
within the formalism of kinetic differential equations
upon the addition of molecules, such as drugs. Re-
cently, some researchers are switching from differ-
ential equations to rule -based modeling (Ciobanu
and Rozenberg, 2004). Molecules are represented as
formal expressions (e.g., strings) that determine the
interaction capabilities of molecules and their mod-
ifications due to interactions. The interaction of two
agents does not require an explicit representation but
it depends on the structure of the interacting agents.
In a similar context, adding an agent (e.g., a drug) to
a system (e.g., a sick pathway) becomes easy as drop-
ping a chemical into a text tube. This property is called
compositionality, i.e. the behaviour of a complex sys-
tem is determined by the behaviour of its elementary
components and can be defined incrementally.
Compositionality seems a key property to break down
the complexity of biological systems and therefore to
study the response of a biological system to drugs.
Among different proposals, formal methods from
concurrency theory and process calculi are promis-
ing (Regev and Shapiro, 2002). Here we refer to β-
binders (Priami and Quaglia, 2005) a bio-inspired pro-
cess calculus based upon pi-calculus (Sangiorgi and
Walker, 2001; Milner, 1999). β-binders is a formalism
for representing interactions among biological enti-
ties, equipped with a stochastic semantics (Degano et
al., 2006) and a simulation environment (Romanel et
al., 2007). In this paper we rely on Markov process
theory (Norris, 1998) to define an Effective Index
(EI), i.e. a measure of the impact of a drug on a sys-
tem. The Effective Index allows in silico comparing
the effect of different drugs and of combination of
drugs. Then we use the Effective Index to plot a dose-
response curve, that is, a graph that relates drug dosage
with organism response.
The paper is organised as follows. After a brief intro-
duction to β-binders modelling in Sect. 2, we present
the model for the NO-cGMP pathway, a relevant bi-
ological example, in Sect. 3 and we discuss its β-
binders model. In Sect. 4 we present the theory under-
lying EI and in Sect. 5 we exploit EI on the NO-cGMP
pathway. Sect. 6 concludes the paper with some final
remarks.
2. THE LANGUAGE
The BetaSIM language is based on the stochastic
extension of β-binders (Priami and Quaglia, 2005;
Degano et al., 2006), a process calculus developed for
better representing the interactions between biological
entities. The main idea of β-binders is to encapsulate
pi-calculus processes into boxes with interaction capa-
bilities. Like the pi-calculus also β-binders is based on
the notion of naming. Thus, we assume the existence
of a countable infinite set N of names (ranged over
by lower-case letters). With respect to the original
syntax, in BetaSIM several modifications have been
introduced. All the modifications are deeply discussed
in (Romanel et al., 2007).
A BetaSIM program, called also β-system, is a tuple
Z=〈B,E, ξ〉 which is a composition of a bio-process
B, a list of eventsE and ambient ξ. The bio-processB
intuitively represents the structure of the system, that
is a set of entities interacting in the same environment,
E represents the list of possible events enabled on the
system and the ambient ξ contains information about
the environment, like the set T of the considered types
(ranged over by∆, Γ0,Σ′, · · · ), a function ρ : N → R
that associates stochastic rates 1 to names in N and
the function α : T 2 → R3, which describes the affin-
ity relation between couples of types. In particular,
given two types ∆ and Γ, the application of α(∆,Γ)
returns a triple of stochastic rates (r, s, t), where r,
denoted with αc(∆,Γ), represents the complexation
rate, s, denoted with αd(∆,Γ), represents decomplex-
ation rate and t, denoted with αi(∆,Γ), represents the
inter-communication rate.
1 A stochastic rate is the single parameter defining an expo-
nential distribution that drives the stochastic behaviour of an ac-
tion (Gillespie, 1977).
The bio-processB and the list of events E are defined
according to the context-free grammar reported in
Fig. 1, where x and y ∈ N , n ∈ N and r ∈ R is a
stochastic rate.
P ::= nil | P |P | !pi.P |M
M ::= pi.P |M +M
pi ::= x(y) | x〈y〉 | (τ, r) | (ch(x,∆), r) |
(die, r) | (hide(x), r) | (unhide(x), r) |
(expose(x, s,∆), r)
β̂ ::= β | βh | βc
B ::= β̂(x, r,∆) | β̂(x, r,∆)B
B ::= Nil | B[P ] | B||B
cond ::= B[P ] : r | |B[P ]| = n | B[P ],B[P ] : r
verb ::= new(n) | split(B[P ],B[P ])
join(B[P ]) | delete
event ::= when (cond) verb
E ::= • | event | event :: E
Fig. 1. BetaSIM language syntax.
Processes generated by the non terminal symbol P
are referred as pi-processes. Boxes are defined as pi-
processes prefixed by specialised binders that rep-
resent interaction capabilities. An elementary beta
binder has the form β(x, r,Γ) (active), βh(x, r,Γ)
(hidden) or βc(x, r,Γ) (complexed), where the name
x is the subject of the beta binder and Γ represents the
type of x. A well-formed beta binder (ranged over by
B, B1, B
′
, · · · ) is a non-empty string of elementary
beta binders where subjects and types are all distinct.
B
∗ denotes either a well-formed beta binder or the
empty string.
A bio-process B is either the deadlock beta-process
Nil or a parallel composition of boxes B[P ]. More-
over, the language is provided with a graphical repre-
sentation of boxes:
P
(x1 : ∆1)r (x2 : ∆2)hr (x3 : ∆3)r
The pairs xi : ∆i represent the sites through which
the box may interact with other boxes. Types ∆i
express the interaction capabilities at xi. The value r
represents the stochastic rate associated to the name
x inside the box, h represents the hidden status and
the black line over the last beta binder represents the
complexed status.
The evolution of the system is formally specified
through the operational semantics of the language,
which is defined with a limited number of operations
and uses a notion of structural congruence ≡. The
structural congruence of BetaSIM uses structural con-
gruences over pi-processes (≡p), bio-processes (≡b)
and lists of events (≡e). Intuitively, this means that
two β-systems Z=〈B,E, ξ〉 and Z ′=〈B′, E′, ξ′〉 are
structurally congruent (Z ≡ Z ′), if their bio-processes
B and B′ and their list of events E and E′ are iden-
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tical up to structure (B ≡b B′ and E ≡e E′) and
their ambients are equal (ξ=ξ′). Moreover, two boxes,
representing interacting entities, are considered of the
same specie only if they are structurally congruent.
Three types of actions describe the evolution of a β-
system.
Monomolecular actions describe the evolution of sin-
gle boxes. More precisely, an intra communication
action allows components to interact within the same
box, the expose action adds a new site of interaction
to the interface of the box containing the expose, the
change action modifies the type of an interaction site,
hide and unhide actions make respectively invisible
and visible an interaction site. Finally, the die action
eliminates the box that performs the action and, recur-
sively, all the boxes directly or indirectly complexed
with them.
Bimolecular actions describe interactions that involve
two boxes. The complex operation creates a dedicated
communication binding between boxes over compat-
ible and unhide elementary beta binders, while the
decomplex operation destroys an already existing ded-
icated binding:
P
(x : ∆)r
‖ Q
(y : Γ)r
⇋ P
(x : ∆)r
‖ Q
(y : Γ)r
The stochastic rates associated to complex and de-
complex operations are, respectively, the complexa-
tion and decomplexation rates derived from the affin-
ity function. In the example, the complexation rate is
αc(∆,Γ), while the decomplexation rate is αd(∆,Γ).
The information about the existing dedicated bindings
is maintained in the ambient.
The inter-communication is the last bimolecular ac-
tion. It enables interaction between boxes over com-
patible and unhide elementary beta binders. Suppose
∆ and Γ be the types associated to the involved el-
ementary beta binders. If αc(∆,Γ) > 0, then the
inter-communication is enabled, with rate αi(∆,Γ),
only after a dedicated communication binding, over
the involved beta binders, has been created by a com-
plex operation. Otherwise, the inter-communication is
simply enabled with rate αi(∆,Γ).
Events can be considered as an implementation of
fsplit and fjoin axioms (Priami and Quaglia, 2005).
An event is the composition of a condition cond
and an action verb, which is triggered only if the
event condition is fulfilled on the structure of the bio-
process representing the system. Let Z=〈B,E, ξ〉 be
the considered β-system. The list E can contain five
types of events. The join event has the form ”when
(B1[P1],B2[P2] : r) join(B[P ])” and is enabled,
with rate r, only if in the bio-process B at least two
boxes B′1[P ′1] and B′2[P ′2] structurally congruent to
B1[P1] and B2[P2] are present. The execution of the
event substitutes one instance of the boxes B′1[P ′1] and
B
′
2[P
′
2] with the box B[P ]. The split event has the
form ”when (B[P ] : r) split(B1[P1],B2[P2])” and
it is enabled, with rate r, only if in the bio-process B
at least a box B′[P ′] structurally congruent to B[P ]
is present. The execution of the event substitutes one
instance of the box B′[P ′] with the boxes B1[P1]
and B2[P2]. Join and split events modify also the
ambient ξ in order to guarantee the consistency with
respect to the existing dedicated bindings. The delete
event has the form ”when (B[P ] : r) delete” and is
enabled, with rate r, only if the bio-processB contains
at least a box B′[P ′] structurally congruent to B[P ].
The execution of the event eliminates one instance
of the box B′[P ′]. The new event can be expressed
in two different forms: ”when (B[P ] : r) new(n)”
and ”when (|B[P ]| = m) new(n)”. The first one is
enabled, with rate r, only if in the bio-process B at
least a box B′[P ′] structurally congruent to B[P ] is
present, while the second one is enabled, with infinite
rate, only if the bio-process B contains exactly m
boxes structurally congruent to B[P ]. The execution
of the event, in both cases, creates n copies of the box
B[P ].
The evolution of a β-system is completely defined by
the associated stochastic reduction system.
Definition 2.1. The β-binders Stochastic Reduction
System (SRS) is referred as S = (Z, r−→s , Z0), where
Z is the set of β-systems, Z0 is the initial β-system
and r−→s ⊆ Z × R × Z is the stochastic reduction
relation.
The value r is a stochastic rate constant and is de-
rived using information in the syntax and in the
ambient of the β-system. Given an initial β-system
Z0=〈B0, E0, ξ0〉, we refer to B0 as the initial bio-
process. Given two β-systems Z1=〈B1, E1, ξ1〉 and
Z2=〈B2, E2, ξ2〉, the parallel compositionZ1 ‖ Z2 is
defined as the β-system 〈B1 ‖ B2, E1 ∪ E2, ξ1 ∪ ξ2〉.
3. EXAMPLE: NO-CGMP PATHWAY
Hypertension is a medical condition where the blood
pressure is chronically elevated. Hypertension affects
almost one third of population in developed countries;
however, a lot of therapies are known and widely used.
One of the approaches is to intervent on the vascular
tone, the degree of constriction experienced by a blood
vessel relative to its maximally dilated state. Vascular
tone is primarily dependent on a protein called myosin
light chain kinase (MLCK). This kinase increases the
phosphorylation of myosin light chains, thereby in-
creasing smooth muscle tension and causing vasocon-
striction. The correspondent phosphatase dephospho-
rylate the myosin light chains, causing vasodilation.
MLCK is activated by the calcium-calmodulin com-
plex, and therefore the activity of this kinase is in-
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Fig. 2. The NO-cGMP pathway in vessel smooth cells
fluenced by intracellular calcium concentration. To
control the level of active MLCK in the cell it is pos-
sible to modulate several signal transduction mecha-
nisms: 1) phosphatidylinositol pathway, 2) G-coupled-
protein (cAMP) pathway, and 3) nitric oxide (NO)-
cGMP pathway (Somlyo and Somlyo, 1994; Kamm
and Stul, 1989).
Nitric oxide (NO) is produced by vascular endothe-
lium, and many other cell types, by the nitric oxide
synthase (NOS), which uses amino acid L-arginine
and oxygen as substrates.
When NO is formed in an endothelial cell it readily
diffuses into an adjacent smooth muscle cell. Here
it binds to a heme domain on guanylyl cyclase and
activates this enzyme, which produce cGMP from
GTP. The increased level of cGMP activates a kinase
that subsequently inhibits the flux of calcium into the
vessel smooth cell, decreasing the concentration of
calmodulin-calcium complexes and therefore the level
of active MLCK.
There is also evidence in literature (Lee et al., 1997;
Rapoport et al., 1983) that increases in cGMP can
also lead to myosin light chain de-phosphorylation by
activating a pertinent phosphatase.
Fig. 2 shows a complete overview of the pathway.
Enzymes are in grey ovals, unknown enzymes having
a dotted outline, and drugs that can interact with
the pathway are in light grey circles. As underlined
in the figure, there are several points in which a
drug can act to influence the cGMP concentration
in vessel smooth muscle cells. N[ω]-monomethyl-L-
arginine (L-NMMA) acts as a competitive inhibitor of
nitric oxide synthase, decreasing the level of NO and
therefore of cGMP. The level of NO can be increased
by the introduction of glyceryl trinitrate (GTN), a
prodrug which is denitrated, by a mechanism that
is widely disputed, to produce 1,2-glyceryl dinitrate
(GDN) and NO (Marsh and Marsh, 2000). Drugs like
sildenafil (Viagra) or E-4021 inhibit cGMP-specific
phosphodiesterase 5, the enzyme responsible for the
degradation of cGMP, and therefore compensate for
reduced NO release and cGMP production (Corbin
and Francis, 1999).
In Fig. 3 part of the model we developed for the
(NO)-cGMP pathway is illustrated. The first line of
boxes in the figure shows the processes involved in
the production of NO and in the synthesis of cGMP.
It is not well established how GTN is transformed
into GDN and NO, so this biochemical reaction is
modelled as a split with rate equal the global observed
rate k1. The synthesis of cGMP is modelled as a com-
munication on binders, as introduced in Sect. 2. The
bio-process GC communicate with GTP through its
binder of type ∆pGTP . The communication changes
the internal structure of the bio-process, transforming
it into a process modelling cGMP . The second line of
boxes in Fig. 3 indicate how PDE5 degrades cGMP
by binding it on the ∆coD domain and sending a d
message (right side of the model). The cGMP bio-
process reacts to the d message; it is transformed into
an empty bio-process. It is also shown how compet-
itive inhibition by Sildenafil drug is modelled with
a compatible domain type ∆D′ . Sildenafil binds to
PDE5 on ∆coD, but do not react to the degrade mes-
sage (left side of the model).
4. EFFECTIVE INDEX
Our aim is to provide formal tools to support decision
processes in drug discovery. Here we introduce the
concept of Effective Index to “measure” the effect of
a drug on a system. Given a SRS, the Effective Index
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PNO = act.r.nil PGC = act.p.r.nil
PGMP = (p.unhide(d).r.nil + d.nil) PPDE5 = d.ch(d,Ω).ch(d,∆coD).r.nil
nil
x : ∆GTN
(GTN )
k1−→s !r.PNO|PNO
x : ∆NO
(NO)
nil
x : ∆GDN
(GDN )
!r.PNO|PNO
act : ∆Heme p : ∆pGTP
(GC)
!r.PGMP |PGMP
p : ∆P d : ∆D
(GTP/cGMP )
PPDE5
d : ∆coD
(PDE5)
PS
d : ∆D′
(Sildenafil)
⇆ PGMP
p : ∆P d : ∆D
(cGMP )
PS
d : ∆D′
(Sildenafil)
PPDE5
d : ∆coD
(PDE5)
⇆ PPDE5
d : ∆coD
(PDE5)
PGMP
p : ∆P d
h : ∆D
(cGMP )
⇆ PPDE5
d : ∆coD
(PDE5)
Fig. 3. Part of the model for the NO-cGMP Pathway
gives the expectation to reach a state that is safe w.r.t.
an observable property.
We start defining a notion of observability of a β-
system. If a type represents the interface (i.e. the
visible part) of a biological entity, then it is natural
to found on types our notion of observable of a β-
system. In particular, the predicate observable type
of a β-system Z , written Z↓Γ, is true if the type Γ
is visible in Z . The predicate Z↓Γ can be extended as
ZnΓ andZ	
n
Γ , meaningZ expresses at least -at most-
n occurrences of Γ, respectively. To express some
combination of this kind of conditions, we define the
concept of observable phenomena.
Definition 4.1. (Observable Phenomena). An observ-
able phenomenon is a formula ϕ ∈ Φ defined by
ϕ ::= ZnΓ | Z	
n
Γ | ϕ ∧ ϕ | ϕ ∨ ϕ
Formulae in Φ allows us to express conditions on the
quantity of visible types of a β-system. For instance, in
the CO-cGMP pathway the level of cGMP is the rele-
vant value. The observable phenomenon ϕ1 = Zn∆D
is true in a β-system where at least n occurrences of
∆D are unhidden, i.e. cGMP is present at an adequate
level of concentration. But ϕ1 is not enough, because
a high level of cGMP may induce a too low blood
pressure. Therefore, cGMP has to be lower than a
value m, expressed by ϕ2 = Z	m∆D , leading to the
observable phenomenon ϕ1 ∧ ϕ2.
Observable phenomena give the ability to quantita-
tively express conditions on a state of a SRS. Fol-
lowing Markov process theory (Norris, 1998), we can
classify the states of a SRS as recurrent and transient.
A state Zi is transient if, starting from state Zi, there
is a non-zero probability that the system will never
return back to Zi. If a state is not transient then it is
said recurrent. Recurrent states formally capture the
idea of “steady states”, i.e. states that offer a stable
behaviour. Given a SRS S, let ΥS ⊆ S be the set
of recurrent states. On a finite SRS, being a recurrent
state is a decidable property and it is characterised by
Th. 3.4.2 in (Norris, 1998). The set of states Ψϕ
S
⊆ ΥS
that satisfies an observable phenomenon ϕ are named
safe states w.r.t. ϕ.
Given a finite SRS S = (Z, r−→s , Z0), the associated
Markov process X(t) is defined as X(t) = Zi if at
time t system S behaves as Zi. The transition rate be-
tween two states Zi and Zj is defined as q(Zi, Zj) =
r, if Zi
r
−→s Zj , written qij . The exit rate of a state Zi
is q(Zi) =
∑
Zj∈Z qij , written qi. The transition rate
and the exit rate completely specifies the stochastic
behaviour of a SRS. In particular, we can compute the
hitting probability, i.e. the probability to reach a state
Zj starting from a state Zi.
Definition 4.2. (Hitting probability). Let S be a finite
SRS (Z , r−→s , Z0). The vector hj = (hji : Zi ∈ Z) of
hitting probabilities of a state Zj ∈ Z is the minimal
non-negative solution to the system of linear equations

h
j
i = 1 if Zi≡Zj∑
Zk∈Z
qikh
j
k = 0 if Zi 6≡ Zj
The value hji is the probability, starting from state Zi
to reach state Zj .
Given a finite SRS S and an observable phenomenon
ϕ, we introduce the Effective Index as the weighted
percentage of recurrent states that are safe w.r.t. ϕ. We
use the hitting probability starting from the initial state
as weights . The formal definition follows.
Definition 4.3. (Effective Index (EI)). Let ϕ ∈ Φ be
an observable phenomenon and S = (Z, r−→s , Z0)
be a finite SRS. The Effective Index of S w.r.t. ϕ is
defined as
ε
S
ϕ =
∑
Zi∈Ψ
ϕ
S
hi0∑
Zi∈ΥS h
i
0
EI is a measure of “how good” is a system S w.r.t.
to an observable phenomenon ϕ. Suppose SH =
(ZH ,
r
−→s , ZH) models a healthy system, SS =
(ZS ,
r
−→s , ZS) is the sick version of SH and let
ϕ a description of the healthy condition (e.g., low
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presence of a certain molecule). Therefore we have
ε
SH
ϕ > ε
SS
ϕ . If β-systems ZD1 and ZD2 model two
drugs D1 and D2 for the sick system SS , we obtain
two treated systems SD1 = (ZD1 ,
r
−→s , ZS ‖ ZD1 )
and SD2 = (ZD2 ,
r
−→s , ZS ‖ ZD2 ). If εSD1ϕ > ε
SD2
ϕ
we can conclude that drug D1 is more effective that
drug D2 w.r.t. the observable phenomenon ϕ.
Finally we can plot a dose-response curve (Kenakin,
2006) relying on EI. A dose-response curve is a graph
that relates the amount of a drug given with the re-
sponse of the organism to that drug. Let ZD be a β-
system describing a drug D for SS . We can define the
family dosage of D as a set of β-systems
ΩZD = {Z | Z≡
n︷ ︸︸ ︷
ZD ‖ . . . ZD , for n ≥ 0}.
The dose-response curve for SS treated with a drug
ZD, where the phenomenon ϕ is observed, is defined
as the set of pairs
σSS,ZDϕ =
{(SZ ,ε
S
ϕ) | SZ = (ZZ ,
r
−→s , ZS ‖ Z), ∀Z ∈ ΩZD}.
5. EFFECTIVE INDEX ON THE ROAD
In this section we explain the use of EI on the NO-
cGMP pathway presented in Sect. 3. In particular, we
explore in our model the interactions between silde-
nafil and glyceryl trinitrate. The ACC/AHA consensus
document on sildenafil (Cheitlin et al., 1999) takes
a cautious approach to interaction between organic
nitrates (e.g., glyceryl trinitrate) and sildenafil. Here,
we test this statement by means of EI, with the pro-
viso that our model and the associated quantitative
measures (i.e. stochastic rates) are not complete, and
therefore this section has to be intended as a tutorial
on EI.
We consider a system SH = (ZH ,
r
−→s , ZH) repre-
senting a healthy pathway. The initial β-system ZH is
defined by the initial bio-process BH
NOS ‖ L-ARG ‖ GC ‖ GTP ‖ PDE5
Box NOS interacts with L-ARG producingNO . Box
NO activates GC , that transforms GTP into cGMP .
Finally, PDE5 degrades cGMP. First, we check if
cGMP is available with the observable phenomenon
ϕ1 = Z
n
∆D
. We compute EI as εSHϕ1 = 0.92,
meaning that finally the level of cGMP is stable. The
sick version of system SH is SS = (ZS ,
r
−→s , ZS),
where the initial bio-process BS is equal to BH . The
difference is in the interaction rate between NOS and
L-ARG: we simulate a disease where some factors
reduce the probability of producing NO from NOS .
The associated EI is εSSϕ1 = 0.26 < ε
SH
ϕ1
.
Glyceryl trinitrate GTN restores the cGMP level pro-
viding an alternative way to produce NO . The GTN
treated SRS is SGTN = (ZGTN ,
r
−→s , ZGTN), where
the initial bio-process is BS ‖ GTN . The associated
EI w.r.t ϕ1 is εSGTNϕ1 = 0.72, that re-establishes a
healthy condition.
Sildenafil Sildenafil acts on cGMP by inhibiting
degradation by cGMP. We build the sildenafil treated
SRS SSil = (ZSil ,
r
−→s , ZSil ), with initial bio-process
BS ‖ Sildenafi . It is known that sildenafil is not really
effective in the case of a lack in NO activation. The
low EI εϕ1
SSil
= 0.41 seems to confirm this fact.
Now, it is interesting to evaluate the interaction
between GTN and Sildenafil on the same sys-
tem. We define a third treated system SGTN-Sil =
(ZGTN-Sil ,
r
−→s , ZGTN-Sil), with initial bio-process
BS ‖ GTN ‖ Sildenafil . The result is an increase in
the EI of the system w.r.t. ϕ1, becoming εϕ1SGTN-Sil =
0.89. This seems to confirm the fact that sildenafil
increase the effect of glyceryl trinitrate (O’Rourke and
Xiong-Jing, 2000). Here, we can taste the flexibility of
our method changing the observable phenomena. In
fact, if we consider also an upper level for the cGMP
availability we have a new observable phenomenon
ϕ2 = Z
n
∆D
∧ Z	m∆D
with n ≤ m. A high level of cGMP may induce a
too low blood pressure with life threatening effects.
We observe that the EI of systems SH , SS , SGTN
and SSil does not change considering observable phe-
nomena ϕ2. But, if we consider the interaction be-
tween glyceryl trinitrate and sildenafil, the EI becomes
ε
ϕ2
SGTN-Sil
= 0.28 < εϕ1
SGTN-Sil
. The level of cGMP may
become to high w.r.t. the observable phenomenon ϕ2.
We conclude our tutorial on EI plotting two dose-
response curves. Fig. 4 plots two curve: D-R1 is the
 1
 0.5
 0
 4 2 0
EI
 R
es
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e
log[GTN dose]
D-R1
D-R2
Fig. 4. Dose-response curve for NO-cGMP
EI for the sick SRS SS treated with increasing dose
of GTN ; D-R2 is the EI for the sildenafil treated
SRS SSil with increasing dose of GTN . In both
curve, the EI is computed with respect to observable
phenomenonϕ2. Curve D-R1 shows the usual sigmoid
shape, while D-R2 behaves as D-R1 until a limit value
for GTN is reached, then the EI decrease quickly.
6. CONCLUSION
We proposed a formal approach to model pharmaco-
dynamics based on executable computer science for-
malisms. We exploited the approach on a running case
6
study concerning pathways and drugs related to the
hypertension. We contributed a measure of effects of
drugs as well as of the dose-response curve. This was
possible due to the system level approach to the mod-
elling and simulation of the phenomena at hand. The
main result of the paper is the feasibility of an auto-
matic and system-level framework to provide decision
support in the drug discovery process. As a further
extension of the proposed approach we are planning
the application of the Effective Index measure to larger
case studies to test its real predictive power.
REFERENCES
Bugrim, A., T. Nikolskaya and Y. Nikolsky (2004).
Early prediction of drug metabolism and toxicity:
systems biology approach and modeling. Drug
Discovery Today 9, 127.
Butcher, E., E. Berg and E. Kunkel (2004). Systems
biology in drug discovery. Nature Biotechnology
22, 1253.
Cheitlin, M.D., A.M. Jr Hutter, R.G. Brindis, P. Ganz,
S. Kaul, l R.O. Jr Russel and S. Kaul (1999).
Use of Sildenafil (Viagra) in Patients With Car-
diovascular Disease. Circulation 99(1), 168–177.
ACC/AHA Expert Consensus Document.
Ciobanu, G. and Rozenberg, G., Eds. (2004). Mod-
elling in Molecular Biology. Springer.
Corbin, J.D. and S.H. Francis (1999). Cyclic GMP
phosphodiesterase-5: target of sildenafil. J Biol
Chem. 274(20), 13729–32.
Degano, P., D. Prandi, C. Priami and P. Quaglia
(2006). Beta-binders for Biological Quantita-
tive Experiments. In: Proc. of the 4th Interna-
tional Workshop on Quantitative Aspects of Pro-
gramming Languages (QAPL 2006). Vol. 164 of
ENTCS. Elsevier. pp. 101–117.
Ekins, S., Y. Nikolsky and T. Nikolskaya (2005).
Techniques: application of systems biology to ab-
sorption, distribution, metabolism, excretion and
toxicity. Trends Pharmacol Sci 26(4), 202–9.
Gillespie, D.T. (1977). Exact stochastic simulation of
coupled chemical reactions. Journal of Physical
Chemistry 81(25), 2340–2361.
Hlavacek, W.S., J.R. Faeder, M.L. Blinov, R.G. Pos-
ner, M. Hucka and W. Fontana (2006). Rules for
modeling signal-transduction systems. Sci STKE.
Jones, D.S. and B.D. Sleeman (2003). Differen-
tial Equations and Mathematical Biology. CRC
Press.
Kamm, K.E. and l J.T. Stul (1989). Regulation of
smooth muscle contractile elements by second
messengers. Annu Rev Physiol. 51, 299313.
Kenakin, T. (2006). A Pharmacology Primer: Theory,
Applications, and Methods. Elsevier.
Kitano, H., Ed. (2001). Foundations of Systems Biol-
ogy. The MIT Press.
Lee, M.R., L. Li and T. Kitazawa (1997). Cyclic GMP
causes Ca2+ desensitization in vascular smooth
muscle by activating the myosin light chain phos-
phatase. J Biol Chem. 272(8), 50635068.
Macheras, P. and A. Iliadis (2005). Modeling in Bio-
pharmaceutics, Pharmacokinetics and Pharma-
codynamics: Homogeneous and Heterogeneous
Approaches. Springer.
Marsh, N. and A. Marsh (2000). A short history
of nitroglycerine and nitric oxide in pharmacol-
ogy and physiology. Clin Exp Pharmacol Physiol
27(4), 313–319.
Milner, R. (1999). Communicating and mobile sys-
tems: the pi-calculus. Cambridge Universtity
Press.
Norris, J.R. (1998). Markov Chains. Cambridge Se-
ries in Statistical and Probabilistic Mathematics.
Cambridge University Press.
O’Rourke, M. and J. Xiong-Jing (2000). Silde-
nafil/nitrate interaction. Circulation.
Priami, C. and P. Quaglia (2005). Beta Binders for
Biological Interactions. In: Computational Meth-
ods in Systems Biology, International Confer-
ence CMSB 2004, Paris, France, May 26-28,
2004, Revised Selected Papers (V. Danos and
V. Vincent Scha¨chter, Eds.). Vol. 3082 of LNCS.
Springer. pp. 20–33.
Rapoport, R. M., M.B. Draznin and F. Murad (1983).
Endothelium-dependent relaxation in rat aorta
may be mediated through cyclic GMP-dependent
protein phosphorylation. Nature 306(5939), 174–
176.
Regev, A. and E. Shapiro (2002). Cells as computa-
tion. Nature 419(6905), 343.
Romanel, A., L. Dematte´ and C. Priami (2007). The
BetaSIM system. Technical Report TR-3-2007.
The Microsoft Research - University of Trento
Centre for Computational and Systems Biology.
Sangiorgi, D. and D. Walker (2001). The pi-calculus: a
Theory of Mobile Processes. Cambridge Univer-
stity Press.
Somlyo, A.P. and A.V. Somlyo (1994). Signal trans-
duction and regulation in smooth muscle. Nature
372(6503), 231236.
7
Appendix A. β-BINDERS CODE
///////////////////////////////////////////////////
// NO-cGMP pathway
///////////////////////////////////////////////////
// Nitric Oxide
let NO_p : pproc = act{e}.r<e>.nil;
let NO : bproc = #(act : 1.0; NOd)
[ !r{}.NO_p | NO_p ];
// Nitric oxide synthease, the enzime that produces NO
let NOS_p : pproc = act<e>.@(2.2).r<e>.nil;
let NOS : bproc = #(act : 1.0; coLAd)
[ !r{}.NOS_p | NOS_p ];
// Its substrate, L-arginine
let L_ARG_p : pproc = act{e}.r<e>.nil;
let L_ARG : bproc = #(act : 1.0; LAd)
[ !r{}.L_ARG_p | L_ARG_p ];
// The active form of NOS, after interaction with L-arginine
// It stays active for a tau
let ActiveNOS : bproc = #(act : 1.0; coLAd)
[ !r{}.NOS_p | @(2.2).r<e>.nil ];
// When NOS is active, produce some NO
when (ActiveNOS: 2.2) split (ActiveNOS, NO);
// Binding to NOS on coLAd, L-NMMA prevents activation
let L_NMMA : bproc = #(x : 1.0; LNAd)
[ nil ];
// Another way to introduce NO: Nitro (Glycerin-tri-nitrate)
let GTN : bproc = #h(no : 1.0; NOd), #(gdn : 1.0; GDNd)
[ NO_p ];
let GDN : bproc = #(gdn : 1.0; GDNd)
[ NO_p ];
// the process of production of NO out of GTN is unknown,
// let’s model it with a simple slipt with rate 2.2
//when (GTN: 2.2) split (GDN, NO);
// The guanylyl cyclase produces cGMP when activated by NO
let GC_p : pproc = act<e>.p{}.r<e>.nil;
let GC : bproc = #(act : 1.0; Heme), #(p : 1.0; pGTP)
[ !r{}.GC_p | GC_p ];
// Methylene blue is a competitiva inhibitor of GC
let MBlue : bproc = #(x : 1.0; coHeme1)
[ nil ];
// This bioprocess encodes the behaviour of both GTP and cGMP
let GMP_p : pproc = (p<e>.unhide(act).unhide(d).act{}.r<e>.nil + d<e>.nil);
let cGMP : bproc = #(p: 1.0; PhosphorG), #h(d : 1.0; DegradeG), #h(act : 1.0; GmpDomain)
[ !r{}.GMP_p | GMP_p ];
// The degraded cGMP process, will be deleted
let cGMP_d : bproc = #(p : 1.0; PhosphorG), #(d : 1.0; DegradeG), #(act : 1.0; GmpDomain)
[ !r{}.GMP_p ];
when (cGMP_d: inf) delete;
// We suppose to have an unlimited amount of GTP
//when (/cGMP/ = 0) new(cGMP, 1);
// After binding on gmpDomain, send degrade message, then detach
// PDE-5 degrades cGMP
let PDE5_p : pproc = d{}.ch(d, gmpRelease).ch(d, coGmpDomain).r<e>.nil;
let PDE5 : bproc = #(d : 1.0; coGmpDomain)
[ !r{}.PDE5_p | PDE5_p ];
// Sildenafil (or E-4021) binds to gmpDomain, but do not react to the degrade message
let Sildenafil : bproc = #(x : 1.0; similGmpDomain)
[ nil ];
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